Samsung Biologics is not just buying PolyPeptide. It is buying into the GLP-1 supply chain

Samsung Biologics Co., Ltd. (KRX: 207940) has launched a public tender offer to acquire PolyPeptide Group AG (SIX: PPGN) for CHF 44.31 per share in cash, valuing the Swiss peptide contract development and manufacturing organisation at approximately CHF 1.46 billion. The transaction has not closed and remains subject to a minimum acceptance threshold of 66⅔% on a fully diluted share count basis, regulatory approvals and other customary offer conditions. PolyPeptide’s board has recommended that shareholders accept the offer, while Draupnir Holding B.V., its largest individual shareholder with about 55.65% of outstanding shares, has committed to tender its stake. The proposed acquisition would push Samsung Biologics beyond its traditional strength in large-molecule biologics into peptide-based active pharmaceutical ingredients used across metabolic, oncology, neurology and rare-disease programmes. The deal is strategically important because demand for peptide manufacturing is rising sharply as obesity and diabetes medicines reshape pharmaceutical capacity planning.

Why is Samsung Biologics moving into peptide manufacturing through PolyPeptide now?

Samsung Biologics has built its reputation as one of the world’s largest biologics contract development and manufacturing organisations, with major facilities in South Korea and a growing international footprint. Its core business has historically been centred on mammalian-cell culture manufacturing, monoclonal antibodies, drug substance production and related biologics services. PolyPeptide gives Samsung Biologics a different manufacturing capability, focused on peptide-based active pharmaceutical ingredients.

That shift matters because the pharmaceutical market is no longer expanding only through conventional biologics. Peptide medicines have become commercially important because of demand in obesity, diabetes and other metabolic disorders, especially around GLP-1 and related mechanisms. As those medicines scale globally, the limiting factor is not only clinical demand or brand strength. It is also the ability to manufacture complex peptide ingredients at reliable quality and volume.

Buying PolyPeptide gives Samsung Biologics immediate access to specialised peptide chemistry, development know-how, customer relationships and manufacturing sites across Europe, the United States and India. Building equivalent expertise organically would take years and would not guarantee the same customer trust or technical depth. In contract manufacturing, time lost to capability building can become market share lost to rivals.

The timing is also linked to PolyPeptide’s recovery. The company reported a strong first half of 2026, with revenue growth, improved profitability and higher exposure to metabolic therapeutics. Samsung Biologics is therefore not buying a distressed asset. It is paying for a platform whose growth profile has become more attractive as peptide demand improves.

The strategic logic is clear. Samsung Biologics wants to become a broader multi-modality manufacturing partner before customers lock long-term supply arrangements elsewhere. In CDMO markets, a supplier’s value increases when it can support more of a client’s pipeline across biologics, peptides, antibody-drug conjugates and emerging modalities. PolyPeptide fills an important gap in that ambition.

How does the CHF 44.31 per share offer balance control, certainty and valuation risk?

The CHF 44.31 offer price represents a 40% premium to PolyPeptide’s undisturbed share price before takeover speculation emerged in April. It also represented a more modest premium to the share price immediately before the transaction announcement because the market had already begun pricing in the possibility of a strategic transaction.

That difference is important. On paper, Samsung Biologics is offering shareholders a substantial premium to the unaffected price. In market reality, PolyPeptide’s shares had already rerated on speculation and improving fundamentals. This makes the offer attractive enough to secure board support and major shareholder backing, but not so generous that Samsung Biologics is buying far above recent takeover-driven expectations.

The structure gives Samsung Biologics a path to control if the tender offer succeeds. The 66⅔% minimum acceptance threshold is significant because it gives the buyer enough support to pursue deeper corporate actions and eventually integrate PolyPeptide more fully. After completion, Samsung Biologics intends to make PolyPeptide a wholly owned subsidiary and delist the company from the SIX Swiss Exchange.

Draupnir Holding’s commitment to tender its roughly 55.65% stake materially reduces deal uncertainty. Samsung Biologics still needs additional acceptance and regulatory clearance, but the largest shareholder support gives the tender offer a strong starting point. For minority shareholders, the trading spread near the offer price indicates that the market sees completion as likely, though not completely risk-free.

The valuation risk sits with Samsung Biologics. The buyer is paying for growth, strategic scarcity and future demand in peptide manufacturing. If peptide capacity remains tight and PolyPeptide continues scaling profitably, the offer could look timely. If demand normalises or customers delay programmes, the acquisition may look expensive relative to the earnings base acquired.

Why has GLP-1 demand made peptide CDMO capacity more strategically valuable?

Peptide manufacturing has moved from a specialist niche to a strategic bottleneck because of the success of peptide-based metabolic medicines. GLP-1 drugs and adjacent obesity and diabetes therapies require reliable peptide supply at scale, and global demand has outpaced the industry’s ability to expand capacity smoothly.

That dynamic has made peptide CDMOs more attractive. Pharmaceutical companies developing metabolic medicines need partners that can support process development, scale-up, regulatory documentation and commercial production. The barrier is not merely owning equipment. Peptide synthesis requires technical expertise, impurity control, analytical capability and years of manufacturing experience.

PolyPeptide’s first-half 2026 performance shows why Samsung Biologics wants the asset now. Metabolic therapeutics generated EUR 161.7 million in revenue and represented about 68% of PolyPeptide’s total revenue during the period. That concentration gives PolyPeptide strong exposure to a fast-growing market, but it also increases the importance of execution in one therapeutic category.

For Samsung Biologics, this exposure offers a chance to participate indirectly in the obesity-drug boom without betting on which branded drug wins. A CDMO can benefit from manufacturing demand across multiple clients and programmes, provided it maintains quality, capacity and customer trust.

The risk is concentration. If PolyPeptide’s growth is too dependent on a limited number of metabolic customers or programmes, Samsung Biologics could inherit revenue volatility disguised as secular growth. The company will need to diversify PolyPeptide’s customer base across metabolics, oncology, neurology and rare diseases while still capturing the GLP-1 capacity wave.

What does PolyPeptide add to Samsung Biologics’ global manufacturing network?

PolyPeptide brings a manufacturing footprint that Samsung Biologics does not currently possess in the same way. The company operates across multiple geographies, including Switzerland, Sweden, Belgium, France, the United States and India. That footprint gives Samsung Biologics greater proximity to pharmaceutical customers in Europe, North America and Asia.

This geographic spread matters because pharmaceutical manufacturing decisions are increasingly influenced by supply-chain resilience, regulatory expectations and customer proximity. Global drugmakers want supply partners that can provide redundancy, quality assurance and regional flexibility. A manufacturing network concentrated in one geography may be efficient, but it can become less attractive when customers are worried about disruption, tariffs or regulatory bottlenecks.

Samsung Biologics has already been expanding internationally, including through a United States manufacturing acquisition and a Netherlands sales office. PolyPeptide would accelerate that shift by adding physical production capability in several strategic markets rather than only expanding sales coverage.

The deal also broadens the company’s customer proposition. Samsung Biologics can support clients developing antibodies and other large-molecule biologics, while PolyPeptide adds peptide active ingredient expertise. Combined correctly, the group can approach pharmaceutical companies with a wider manufacturing menu.

Integration will determine whether that broader menu creates real value. A customer developing a peptide medicine will not automatically choose Samsung Biologics because it also manufactures antibodies. Cross-selling works only when the combined organisation offers technical depth, reliable service and clear accountability. The danger is that a broader portfolio becomes harder to navigate unless the integration is handled with discipline.

How do PolyPeptide’s first-half 2026 results support the takeover logic?

PolyPeptide’s preliminary first-half 2026 numbers make the acquisition easier to justify. Revenue increased 41.6% to EUR 236.6 million, while the EBITDA margin improved to 20.7% from 2.7% in the prior-year period. The result for the period improved to about EUR 9 million from a loss of EUR 26.5 million.

These numbers indicate that PolyPeptide is emerging from a difficult operating period with stronger demand, better utilisation and improved profitability. That is precisely the phase when a strategic buyer may be willing to pay before the recovery becomes fully reflected in earnings and valuation.

The development pipeline also strengthened. PolyPeptide reported that Phase III projects in its portfolio increased to 37 from 30 at the end of 2025. A larger late-stage project base can support future commercial manufacturing revenue if those customer programmes advance to approval and launch.

The company also upgraded full-year guidance, expecting 25% to 30% revenue growth at constant currency, a high-teens EBITDA margin and capital expenditure equal to 15% to 20% of revenue. That guidance shows both opportunity and capital intensity. Growth is strong, but capacity expansion remains expensive.

For Samsung Biologics, the improved profitability supports the investment case, while the high capital needs explain why PolyPeptide may benefit from a larger parent. A bigger owner can fund expansion more comfortably, support customer commitments and absorb investment cycles. For PolyPeptide shareholders, the offer provides cash certainty while the business still faces the execution demands of scaling.

Why did Samsung Biologics shares react cautiously despite the strategic fit?

Samsung Biologics shares closed at KRW 1,485,000 on July 31, down 2.75% for the session and below the stock’s 52-week high of KRW 1,987,000. The shares remain well above the 52-week low of KRW 982,000, indicating that investors still assign substantial value to the company’s CDMO growth platform.

The cautious reaction to the PolyPeptide deal is understandable. Strategic fit does not automatically make an acquisition financially attractive. Samsung Biologics is using capital to buy a company in a specialised market where demand is strong but execution requirements are demanding. Investors must now evaluate whether the acquisition will improve growth, margins and customer relevance enough to justify the price and integration risk.

Samsung Biologics also reported strong second-quarter 2026 results, with revenue of KRW 1.321 trillion and operating profit of KRW 586 billion. First-half revenue reached KRW 2.578 trillion, with operating profit of KRW 1.167 trillion. Those results show that the existing business is already performing well, which raises the bar for any acquisition.

When a company is executing strongly, investors often become more sceptical of large expansion deals. They ask whether management is buying because the opportunity is exceptional or because it wants to accelerate growth beyond what organic expansion can deliver. That scepticism is healthy. CDMO acquisitions can create scale, but they can also create culture clashes, customer overlap and operational distraction.

The market does not appear to be rejecting the transaction. It is simply not giving Samsung Biologics full credit before the tender process, regulatory approvals and integration plan are complete. For a buyer close to a high-growth manufacturing cycle, that caution is less a red flag and more a reminder that shareholders prefer execution evidence to strategic adjectives.

Why is PolyPeptide trading close to the offer price but still below the CHF 44.31 cash value?

PolyPeptide shares have moved close to Samsung Biologics’ CHF 44.31 cash offer, recently trading around the CHF 43.85 to CHF 44.05 range. That narrow spread suggests that investors expect the transaction to complete, but still assign some risk to timing, regulatory review and tender-offer mechanics.

The remaining discount is normal in announced cash tender offers. Shareholders do not receive the offer price immediately. They must wait for the offer document, main offer period, acceptance threshold, regulatory approvals and settlement. During that time, there is always some probability, however small, that a transaction could be delayed, modified or fail.

PolyPeptide’s board recommendation and Draupnir Holding’s tender commitment reduce that risk materially. With the largest individual shareholder already supporting the transaction, Samsung Biologics has a strong base from which to reach the minimum acceptance level. That is why the market has priced PolyPeptide close to the offer.

The absence of a larger spread also implies limited expectation of a competing offer. PolyPeptide went through a strategic review process after indications of interest emerged, and the current deal appears to have resulted from competitive discussions. That reduces the likelihood that another bidder suddenly appears with a materially higher price.

For PolyPeptide shareholders, the investment case has shifted from standalone growth to deal completion. The upside to CHF 44.31 is limited, while the downside would be meaningful if the offer fails and the stock returns to trading mainly on earnings, capacity investment and customer concentration.

How could the acquisition reshape competition among global CDMOs?

If completed, the deal would strengthen Samsung Biologics’ position as a broader multi-modality CDMO. Competitors in biologics, peptides and pharmaceutical outsourcing would face a larger rival with strong balance-sheet capacity, global customers and expanded technical capabilities.

The immediate competitive effect may be most visible in peptide manufacturing. PolyPeptide already has deep heritage in peptide active ingredient development and production. Under Samsung Biologics, it could gain access to additional capital, global commercial reach and potentially stronger large-pharma relationships.

This may pressure standalone peptide CDMOs and integrated suppliers to accelerate investment. Customers developing GLP-1, oncology and rare-disease peptide therapies want long-term partners capable of supporting development through commercial launch. If Samsung Biologics can offer broader capacity and financial stability, rivals may need to respond with expansion, partnerships or consolidation.

The transaction also reinforces a wider industry trend. CDMOs are moving beyond single-modality expertise because pharmaceutical pipelines are becoming more diverse. Large customers increasingly prefer partners that can support several therapeutic formats, from antibodies and antibody-drug conjugates to peptides, mRNA and complex biologics.

However, scale does not always beat specialisation. Some customers may prefer highly focused suppliers for technically sensitive peptide work. Samsung Biologics must therefore preserve PolyPeptide’s specialist identity rather than flatten it into a generic manufacturing unit. The value lies in adding scale to expertise, not replacing expertise with corporate process.

What are the biggest risks before and after the PolyPeptide tender offer closes?

The first risk is deal completion. The tender offer still requires minimum acceptance of 66⅔%, regulatory clearances and other conditions. The offer prospectus is expected by the end of August 2026, and completion is expected toward the end of the year, but the transaction is not closed.

The second risk is customer retention. CDMO customers are cautious about manufacturing continuity. Samsung Biologics must reassure PolyPeptide’s clients that ownership change will not disrupt supply, confidentiality, quality systems or strategic priorities.

The third risk is capacity execution. PolyPeptide’s growth requires sustained capital expenditure, including expansion projects tied to solid-phase peptide synthesis and other manufacturing capabilities. Samsung Biologics must fund capacity at the right pace. Too little investment could leave demand unmet, while too much could create underused assets if customer programmes slow.

The fourth risk is cultural integration. PolyPeptide’s scientific and manufacturing expertise has been built over decades. Samsung Biologics needs to retain key employees and protect technical know-how. The easiest way to destroy a specialist CDMO is to treat it like an interchangeable factory.

The fifth risk is customer concentration in metabolic therapeutics. Strong GLP-1 demand is attractive, but heavy reliance on one category can expose the business to customer concentration, pricing pressure or programme-specific volatility. Diversification across oncology, neurology and rare diseases will be important.

The sixth risk is valuation. Samsung Biologics is paying for growth and scarcity. If peptide demand remains strong, that may look disciplined. If the market cools or PolyPeptide margins fail to improve further, investors may question whether Samsung Biologics bought near the top of the cycle.

What should investors watch between now and expected year-end completion?

The first milestone is publication of the offer prospectus, expected no later than August 31, 2026. That document will provide detailed terms, timing and conditions for PolyPeptide shareholders.

The second milestone is acceptance during the main offer period. Draupnir Holding’s commitment gives Samsung Biologics a strong start, but the final acceptance level will determine how cleanly the buyer can move toward full ownership and delisting.

The third issue is regulatory review. CDMO transactions generally raise fewer product-market concerns than drug mergers, but manufacturing capacity, customer relationships and geographic presence can still attract scrutiny in relevant jurisdictions.

The fourth issue is PolyPeptide’s operating performance through the second half of 2026. Strong revenue growth, margin improvement and customer progress would reinforce the acquisition logic. Any slowdown could make the price look less attractive.

The fifth issue is Samsung Biologics’ integration plan. Investors will want to know whether PolyPeptide will operate as a distinct specialist platform or be more deeply folded into Samsung Biologics’ broader CDMO structure. The former may preserve expertise better, while the latter may create more operational synergies.

The sixth issue is capital allocation. Samsung Biologics is already investing in Plant 5, integrating its Rockville site and expanding global operations. Adding PolyPeptide increases growth options, but also raises the number of projects competing for management attention.

The acquisition could turn Samsung Biologics into a more complete biopharmaceutical manufacturing partner. It could also test whether the company can expand beyond its biological comfort zone without diluting the operating discipline that made it valuable in the first place.

Key takeaways on what Samsung Biologics’ PolyPeptide offer means for the CDMO market

• Samsung Biologics has launched a CHF 44.31 per share cash tender offer for PolyPeptide, valuing the Swiss company at about CHF 1.46 billion.
• The transaction has not closed and remains subject to minimum acceptance, regulatory approvals and other customary offer conditions.
• PolyPeptide’s board has recommended the offer, while Draupnir Holding has committed to tender its approximately 55.65% stake.
• The offer is expected to complete toward the end of 2026 if conditions are satisfied.
• PolyPeptide gives Samsung Biologics specialised peptide active ingredient capabilities across Europe, the United States and India.
• The acquisition would broaden Samsung Biologics beyond biologics manufacturing into peptide therapeutics, including GLP-1-related supply chains.
• PolyPeptide’s first-half 2026 revenue rose strongly, with metabolic therapeutics representing about 68% of total revenue.
• Samsung Biologics shares closed at KRW 1,485,000 on July 31, showing that investors remain constructive but cautious on acquisition execution.
• PolyPeptide trades close to the CHF 44.31 offer, implying high but not complete confidence in deal completion.
• The strategic return will depend on customer retention, capacity expansion, integration discipline and whether peptide demand stays structurally strong.